Aloglutamol

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Aloglutamol
Accession Number
DB13650
Type
Small Molecule
Groups
Experimental
Description

Aloglutamol is an antacid, an aluminium compound. It is a salt of aluminium, gluconic acid, and tris. Proprietary names include Altris, Pyreses, Tasto and Sabro.

Structure
Thumb
Synonyms
Not Available
International/Other Brands
Altris / Pyreses / Sabro / Tasto
Categories
UNII
I670EI8M2N
CAS number
13755-41-4
Weight
Average: 377.2786
Monoisotopic: 377.111388678
Chemical Formula
C10H24AlNO12
InChI Key
GJJYZOBRHIMORS-GQOAHPRESA-K
InChI
InChI=1S/C6H12O7.C4H11NO3.Al.2H2O/c7-1-2(8)3(9)4(10)5(11)6(12)13;5-4(1-6,2-7)3-8;;;/h2-5,7-11H,1H2,(H,12,13);6-8H,1-3,5H2;;2*1H2/q;;+3;;/p-3/t2-,3-,4+,5-;;;;/m1..../s1
IUPAC Name
2-amino-2-(hydroxymethyl)propane-1,3-diol; dihydroxyalumanyl (2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanoate
SMILES
NC(CO)(CO)CO.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(=O)O[Al](O)O

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
16-BromoepiandrosteroneThe bioavailability of 16-Bromoepiandrosterone can be decreased when combined with Aloglutamol.
19-norandrostenedioneThe bioavailability of 19-norandrostenedione can be decreased when combined with Aloglutamol.
2,5-Dimethoxy-4-ethylamphetamineAloglutamol may decrease the excretion rate of 2,5-Dimethoxy-4-ethylamphetamine which could result in a higher serum level.
2,5-Dimethoxy-4-ethylthioamphetamineAloglutamol may decrease the excretion rate of 2,5-Dimethoxy-4-ethylthioamphetamine which could result in a higher serum level.
3,4-MethylenedioxyamphetamineAloglutamol may decrease the excretion rate of 3,4-Methylenedioxyamphetamine which could result in a higher serum level.
4-Bromo-2,5-dimethoxyamphetamineAloglutamol may decrease the excretion rate of 4-Bromo-2,5-dimethoxyamphetamine which could result in a higher serum level.
5-androstenedioneThe bioavailability of 5-androstenedione can be decreased when combined with Aloglutamol.
AcepromazineAloglutamol can cause a decrease in the absorption of Acepromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
AceprometazineAloglutamol can cause a decrease in the absorption of Aceprometazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
AcetaminophenAloglutamol can cause a decrease in the absorption of Acetaminophen resulting in a reduced serum concentration and potentially a decrease in efficacy.
Food Interactions
Not Available

References

General References
Not Available
External Links
ChemSpider
28426726
ChEMBL
CHEMBL3707299
Wikipedia
Aloglutamol
ATC Codes
A02AB06 — Aloglutamol

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
logP-4.3ChemAxon
pKa (Strongest Acidic)11.68ChemAxon
pKa (Strongest Basic)-2.8ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count8ChemAxon
Hydrogen Donor Count7ChemAxon
Polar Surface Area167.91 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity42.47 m3·mol-1ChemAxon
Polarizability21.73 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as sugar acids and derivatives. These are compounds containing a saccharide unit which bears a carboxylic acid group.
Kingdom
Organic compounds
Super Class
Organic oxygen compounds
Class
Organooxygen compounds
Sub Class
Carbohydrates and carbohydrate conjugates
Direct Parent
Sugar acids and derivatives
Alternative Parents
Medium-chain hydroxy acids and derivatives / Medium-chain fatty acids / Beta hydroxy acids and derivatives / Hydroxy fatty acids / Monosaccharides / Secondary alcohols / 1,2-aminoalcohols / Carboxylic acid salts / Polyols / Carboxylic acids
show 10 more
Substituents
Gluconic_acid / Medium-chain hydroxy acid / Medium-chain fatty acid / Beta-hydroxy acid / Hydroxy fatty acid / Fatty acyl / Fatty acid / Hydroxy acid / Monosaccharide / 1,2-aminoalcohol
show 22 more
Molecular Framework
Not Available
External Descriptors
Not Available

Drug created on June 23, 2017 14:46 / Updated on October 01, 2018 15:36